Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company reported Q3 2025 revenue of 4.2 billion HKD, a year-on-year increase of 27.2%, achieving a historical high for quarterly revenue, while profit was 317 million HKD, down 16.4% [1] - The company announced a new stock incentive plan, granting stock options and reward shares to employees, indicating ongoing commitment to employee motivation [1] - HNB product shipments have significantly increased, with positive feedback on the Glo Hilo product in Japan, and plans for expansion into European markets [2] - The ODM business has shown growth due to increased compliance orders, while the self-branded products have successfully iterated flagship offerings and improved local marketing efforts [3] - The company is expected to benefit from the regulatory crackdown on illegal products in the vaping industry, leading to a recovery in the market [4] Financial Summary - The company is projected to achieve revenues of 141.75 billion HKD, 166.89 billion HKD, and 194.95 billion HKD for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 20.14%, 17.73%, and 16.81% [4][11] - The net profit attributable to the parent company is expected to be 10.80 billion HKD, 19.34 billion HKD, and 26.52 billion HKD for the same years, with growth rates of -17.15%, 79.13%, and 37.10% [4][11] - The current market capitalization is approximately 96.43 billion HKD, with a closing price of 15.57 HKD per share [5]

Core Viewpoint - The company's performance in Q3 2025 aligns with expectations, showing a revenue increase but a decline in net profit due to stock incentive expenses and ongoing high R&D investments [1][2]. Financial Performance - Revenue for the first three quarters of 2025 reached 10.21 billion yuan, a year-on-year increase of 21.8% - Net profit attributable to shareholders was 810 million yuan, a year-on-year decrease of 23.8% - Adjusted net profit after stock incentive expenses was 1.18 billion yuan, a slight increase of 0.1% [1]. Development Trends - Glo Hilo is expanding steadily in Japan and Poland, with positive sales momentum in the European vaping market - The company expects to see growth in revenue from HNB products and compliant vaping products in Europe, despite regulatory challenges in the U.S. [1][2]. Short-term Profitability and R&D - Short-term profitability may be slightly pressured due to increased orders from small clients in Europe and initial sales of HNB heating devices - The company is increasing R&D investments in vaping medical and HNB new businesses, which may impact net profit in Q3 2025 [2]. Long-term Growth Prospects - The company anticipates accelerated global expansion of Glo Hilo by 2026, which is expected to drive revenue growth - The vaping medical segment is expected to commercialize, opening up long-term growth opportunities [2]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders in 2025 has been reduced by 20% to 1.05 billion yuan, while the 2026 forecast has been increased by 11% to 1.88 billion yuan - The current stock price corresponds to a 47 times P/E ratio for 2026, with a target price maintaining a 69 times P/E ratio, indicating a potential upside of 46% [2].

Core Viewpoint - The report from CICC indicates a downward adjustment of 20% in the forecast for Smoore International's (06969) 2025 net profit attributable to shareholders, bringing it to 1.05 billion yuan, while the 2026 net profit forecast is raised by 11% to 1.88 billion yuan, reflecting a positive outlook driven by HNB product sales [1] Group 1: Financial Performance - For the first three quarters of 2025, the company reported revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, while net profit attributable to shareholders was 810 million yuan, a decrease of 23.8%. Adjusted net profit after accounting for stock incentive expenses was 1.18 billion yuan, showing a slight increase of 0.1% [2] - Quarterly net profit figures for 2025 were 200 million yuan in Q1, 300 million yuan in Q2, and 317 million yuan in Q3, with year-on-year changes of -43.4%, +12.7%, and -16.4% respectively, aligning with CICC's expectations [2] Group 2: Market Expansion and Product Development - The Glo Hilo brand is expanding steadily in Japan and Poland, with the company positioned as a leader in flavor restoration, heating speed, and brand image. The positive sales momentum of heating devices is expected to contribute to revenue [3] - The company anticipates continued growth in the European vaping market, driven by differentiated compliant products from small brands, while orders in the U.S. are expected to remain stable despite regulatory tightening [3] - The company is leading in global market share for open-system proprietary brands, with expectations of continued year-on-year growth in Q3 2025 [3] Group 3: Profitability and R&D Investment - Short-term profitability may be slightly pressured due to increased orders from small customers in the European vaping market and initial sales of HNB heating devices. However, profitability is expected to improve as orders for vaping products increase and high-margin HNB products gain traction [4] - The company is increasing R&D investments in vaping medical and HNB new businesses, which, combined with the impact of stock incentive expenses, resulted in a year-on-year net profit decline of 16.4% and an adjusted net profit increase of 4% in Q3 2025 [4] Group 4: Long-term Growth Prospects - The company expects Glo Hilo to accelerate its global expansion in 2026, with concentrated shipments of HNB products likely to drive revenue growth. New products, technologies, and customers are anticipated to open up long-term opportunities [5] - In the vaping medical sector, the acceleration of complex generic drug development and the gradual realization of innovative drug collaborations are expected to lead to commercialization, providing long-term growth potential [5]

Core Viewpoint - The report from CICC indicates a downward adjustment in the net profit forecast for Smoore International (06969) for 2025 by 20% to 1.05 billion yuan, while the 2026 net profit forecast is raised by 11% to 1.88 billion yuan, reflecting a strong performance driven by HNB product sales [1] Group 1: Financial Performance - For the first three quarters of 2025, the company reported revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, while the net profit attributable to shareholders was 810 million yuan, a year-on-year decrease of 23.8% [2] - Adjusted for stock incentive expenses, the net profit attributable to shareholders was 1.18 billion yuan, showing a slight year-on-year increase of 0.1% [2] - Quarterly net profit for 1Q, 2Q, and 3Q of 2025 was 200 million, 300 million, and 317 million yuan respectively, with year-on-year changes of -43.4%, +12.7%, and -16.4% [2] Group 2: Market Expansion and Product Performance - The Glo Hilo brand is expanding steadily in Japan and Poland, with the company positioned as a leader in flavor restoration, heating speed, and brand image [3] - The company anticipates continued growth in the European vaping market, driven by differentiated compliant products amid regulatory changes [3] - The open-system self-owned brand is leading in global market share, with expectations of continued year-on-year growth in 3Q25 [3] Group 3: Cost Structure and R&D Investment - Short-term profitability is impacted by the allocation of stock incentive expenses, while R&D investments remain high [4] - The company expects slight pressure on gross margins in the short term due to increased orders from small clients in the European vaping market and initial sales of HNB heating devices [4] - The net profit and adjusted net profit for 3Q25 showed year-on-year changes of -16.4% and +4% respectively [4] Group 4: Long-term Growth Prospects - The company is optimistic about the global expansion of HNB products, which is expected to drive performance in the coming years [5] - The combination of drug-device complex generic drug development and innovative drug collaborations is anticipated to lead to commercialization in the vaping medical sector, opening up long-term growth opportunities [5]

Core Viewpoint - Smoore International (06969) reported significant revenue growth in Q3 2025, reaching 4.197 billion yuan, a 27.2% year-on-year increase, but faced declining profitability with a net profit of 317 million yuan, down 16.4% year-on-year [1][10] Revenue Performance - The company achieved a record high quarterly revenue, with total revenue for the first three quarters of 2025 at 10.21 billion yuan, up 21.8% year-on-year [1] - Revenue growth was primarily driven by the enterprise client business and proprietary brand business, with overseas markets, particularly Europe and the US, contributing over 97% of revenue [1][4] Business Segments - Smoore International operates two main business segments: enterprise client business and proprietary brand business, both focusing on overseas markets, especially Europe [4] - The enterprise client business generated 2.734 billion yuan in Europe and other countries in the first half of 2025, a 38% increase, accounting for 57.7% of this segment's revenue [4] - The proprietary brand business saw revenue of 1.07 billion yuan in Europe and other countries, a 15.1% increase, contributing 84% of its segment revenue [4][5] Market Strategy - The company shifted its market strategy post-2022, focusing on overseas expansion after facing declines due to pandemic-related supply chain issues and domestic regulatory challenges [2] - The US and China markets showed weaker performance, with a 6.7% decline in the US proprietary brand revenue and only 0.5% revenue contribution from China [5] Research and Development - Smoore International invested heavily in R&D, with total R&D expenditure of 722 million yuan in the first half of 2025, focusing on electronic nicotine delivery systems [6][8] - The company holds a significant number of patents, with 839 new applications globally, ensuring a competitive edge in the electronic vaporization market [8] Profitability Challenges - The company's profitability is under pressure, with net profit margins declining from 20.67% in 2022 to 7.92% in the first three quarters of 2025 [9] - Increased R&D and operational costs have led to a rise in expense ratios, impacting overall profitability despite revenue growth [9] Market Outlook - Analysts have mixed views on Smoore International's future, with some predicting revenue growth driven by electronic cigarette sales but cautioning about declining net profits due to rising costs [10] - The company's growth potential hinges on regulatory conditions in key markets, with expectations for profitability to improve as overseas markets and new product lines continue to develop [10]

Core Viewpoint - Smoore International (06969) reported significant revenue growth in Q3 2025, reaching 4.197 billion yuan, a 27.2% year-on-year increase, but faced declining profitability with a net profit of 317 million yuan, down 16.4% year-on-year [1][11] Revenue Performance - The company achieved a record high quarterly revenue, with total revenue for the first three quarters of 2025 at 10.21 billion yuan, up 21.8% year-on-year [1] - Revenue growth was primarily driven by the enterprise client business and proprietary brand business, with overseas markets, particularly Europe and the US, contributing over 97% of revenue [1][5] Profitability Challenges - Despite revenue growth, net profit has declined for four consecutive years, with a net profit margin dropping to 7.92% in the first three quarters of 2025 [1][10] - The gross margin has also decreased from 43.3% in 2022 to 37.3% in the first half of 2025, indicating pressure on profitability [10] Business Segments - The company operates two main business segments: enterprise client business and proprietary brand business, both focusing on overseas markets, especially Europe [5][6] - The enterprise client business generated 2.734 billion yuan in Europe and other countries in the first half of 2025, a 38% increase, accounting for 57.7% of this segment's revenue [5] - The proprietary brand business saw revenue of 1.07 billion yuan in Europe and other countries, a 15.1% increase, contributing 84% of its segment revenue [5] Research and Development - Smoore International has invested heavily in R&D, with total R&D expenditure of 722 million yuan in the first half of 2025, focusing on electronic nicotine delivery systems [7][9] - The company holds a significant number of patents, with 839 new patent applications globally, indicating a strong commitment to innovation [9] Market Outlook - The company has shifted its market strategy post-2022, focusing on overseas expansion to recover from previous declines in revenue [2][11] - Despite challenges in the US and China markets, the company anticipates continued high growth in Europe and other international markets [6][11] Investment Sentiment - Analysts have mixed views on Smoore International, with some predicting revenue growth driven by electronic cigarette sales but cautioning about rising costs and declining net profit [11] - Others remain optimistic about the company's potential for recovery and growth, particularly in the HNB product line [11]

Core Viewpoint - Guojin Securities maintains a "Buy" rating for Smoore International (06969), projecting EPS for 2025-2027 to be 0.22, 0.39, and 0.59 yuan respectively, with corresponding PE ratios of 67, 37, and 25 times at the current stock price [1] Financial Performance Summary - For Q1-Q3 2025, the company achieved revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, with net profit and adjusted net profit (excluding stock incentive expenses) at 809 million and 1.182 billion yuan, reflecting a year-on-year decrease of 23.8% and an increase of 0.1% respectively [1] - In Q3 2025, the company reported revenue of 4.197 billion yuan, a year-on-year increase of 27.2%, with net profit and adjusted net profit at 317 million and 444 million yuan, showing a year-on-year decrease of 16.4% and an increase of 4.0% respectively [1][2] Business Segment Insights - The HNB (Heated Not Burn) business is expected to significantly contribute to revenue, with the launch of the hilo product in Japan and Poland driving sales growth, alongside increasing regulatory scrutiny on illegal products in Europe and the US [1] - The vaping business is anticipated to achieve double-digit growth in Q3 2025, benefiting from market shifts in Europe and increased enforcement against illegal products in the US [1] - The company is focusing on the iteration and expansion of its own brand series, with a steady increase in market share, and expects favorable growth in its APV (Advanced Personal Vaporizer) business [1][2] Profitability Outlook - Adjusted net profit for Q3 2025 increased by 4.0% to 444 million yuan, with an adjusted net profit margin of 10.6%, down from 11.5% in Q3 2024 [2] - Despite a year-on-year decline in profit margin, the overall performance remains strong, with future profit elasticity expected due to the anticipated increase in profitability from HNB products as sales volume grows [2] - The company is also increasing R&D investments in medical nebulization, with recent FDA acceptance of a subsidiary's abbreviated new drug application indicating progress in this area [2] Market Expansion and Growth Potential - The expansion of the legal vaping market in Europe and the US is a prevailing trend, with the HNB product glo hilo starting promotions in Poland, indicating potential for global sales growth [2] - The company is positioned as a unique player deeply integrated into the supply chains of both vaping and HNB products, suggesting a clear path for future growth [2]

Core Viewpoint - Guojin Securities maintains a "Buy" rating for Smoore International (06969), projecting EPS for 2025-2027 to be 0.22, 0.39, and 0.59 yuan respectively, with current stock prices corresponding to PE ratios of 67, 37, and 25 times [1] Financial Performance - For Q1-Q3 2025, the company achieved revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, with net profit and adjusted net profit (excluding stock incentive costs) at 808 million and 1.182 billion yuan, reflecting a year-on-year decrease of 23.8% and an increase of 0.1% respectively [1] - In Q3 2025, the company reported revenue of 4.197 billion yuan, a year-on-year increase of 27.2%, with net profit and adjusted net profit at 317 million and 444 million yuan, showing a year-on-year decrease of 16.4% and an increase of 4.0% respectively [1][2] Business Segments - The HNB (Heat-not-Burn) business is expected to significantly contribute to revenue, with the launch of the hilo product in Japan and Poland driving sales growth [1] - The vaping business is anticipated to achieve double-digit growth in Q3 2025, benefiting from regulatory changes in Europe and increased enforcement against illegal products in the U.S. [1] - The company is focusing on the iteration and expansion of its own brand series, with a steady increase in market share for its OBM (Own Brand Manufacturing) business [1] Profitability Outlook - The adjusted net profit for Q3 2025 increased by 4.0% to 444 million yuan, with an adjusted net profit margin of 10.6%, slightly down from 11.5% in Q3 2024 [2] - Despite a decline in profit margin, the overall performance remains strong, with future profit elasticity expected due to the anticipated increase in HNB business profitability as sales volume grows [2] Market Expansion - The expansion of the legal vaping market in Europe and the U.S. is a significant trend, with the HNB product glo hilo starting promotions in Poland, indicating potential for global sales growth [3] - The company is positioned as a unique player deeply involved in the supply chains of both vaping and HNB products, suggesting a clear path for future growth [3]

Core Viewpoint - The company reported a significant revenue increase in Q3 2025, driven by the HNB and vaping business, despite a decline in net profit due to initial low-margin sales and ongoing investments in R&D [1][2] Financial Performance - For Q1-Q3 2025, the company achieved revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, with net profit of 809 million yuan, down 23.8% [1] - In Q3 2025, revenue reached 4.197 billion yuan, up 27.2% year-on-year, while net profit was 317 million yuan, a decrease of 16.4% [1] Business Analysis - The HNB business is expected to contribute significantly to revenue, with the HNB product "hilo" launched in Japan and Poland, leading to strong sales [1] - The vaping business is projected to see double-digit growth in Q3 2025, benefiting from regulatory changes in Europe and increased enforcement against illegal products in the U.S. [1] - The company is focusing on brand development and market expansion, with a steady increase in market share for its own brands [1] - The adjusted net profit for Q3 2025 showed a year-on-year increase of 4.0% to 444 million yuan, with an adjusted net profit margin of 10.6% [1] Growth Outlook - The expansion of the legal vaping market in Europe and the U.S. is expected to continue, with the HNB product "glo hilo" gaining traction in Poland [2] - The company is positioned uniquely in the market as a supplier in both vaping and HNB categories, indicating a strong growth potential [2] Earnings Forecast and Valuation - The company forecasts EPS of 0.22, 0.39, and 0.59 yuan for 2025-2027, with corresponding PE ratios of 67, 37, and 25 times [2]

Group 1 - The company reported Q3 2025 financial data, with revenue of 4.197 billion yuan, a year-on-year increase of 27.5%, and adjusted profit of 444 million yuan, a year-on-year increase of 4.8% [1] - HNB is expected to become a major growth driver, with significant revenue increase anticipated due to the pre-production nature and the full rollout of hilo in Japan, leading to substantial sequential growth in sales [1] - The ODM+ strategy has been further validated, with satisfactory growth from new product iterations, and overall growth expected to exceed double digits as new compliant products are launched [1] Group 2 - Emerging businesses are expected to elevate the company's valuation, with the subsidiary successfully submitting an ANDA for Breo Ellipta, which is used for asthma and COPD treatment, indicating potential for further valuation uplift [1] - The company anticipates that HNB will become a primary source of profit release by 2026, with traditional vaping business valuation solidifying [2] - Revenue projections for 2025-2027 are 14.2 billion, 16.9 billion, and 19.5 billion yuan, with corresponding net profits of 1.395 billion, 1.898 billion, and 2.368 billion yuan, leading to PE ratios of 64.53x, 47.44x, and 38.02x respectively, maintaining a "buy" rating [2]